KM Research Hub
← 返回论文库
部分完成 入排:符合 图源:可得 入排置信度 0.98

Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.

Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M Arance, Stephane Dalle, C Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Iván Márquez-Rodas, Marcus O Butler, Anna Maria Di Giacomo, Luis de la Cruz-Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A Fecher, Michael Millward, Nikhil I Khushalani, Paola Queirolo, Georgina V Long, Maurice Lobo, Margarita Askelson, Paolo A Ascierto, James Larkin

J Clin Oncol 42(31) 3702-3712

PMID39102624
PMCIDPMC11527380
DOI10.1200/JCO.23.01448
发表日期2024-08-05
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

PURPOSE: In phase III CheckMate 238, adjuvant nivolumab significantly improved recurrence-free survival compared with ipilimumab in patients with resected stage IIIB-C/IV melanoma without a significant difference in overall survival (OS). Here, we investigate progression-free survival (PFS) and OS after postrecurrence systemic therapy. PATIENTS AND METHODS: Patients 15 years or older with resected stage IIIB-C/IV melanoma were stratified by stage and tumor PD-L1 status and randomly assigned to receive nivolumab 3 mg/kg every 2 weeks, or ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks for 1 year or until disease recurrence, unacceptable toxicity, or withdrawal of consent. Patients with recurrence in each group were assessed for PFS and OS from subsequent systemic therapy (SST) initiation per recurrence timing (≤12 months [early] v >12 months [late] from initial therapy). RESULTS: Recurrences occurred in 198 (44%) of 453 nivolumab-treated patients (122 early, 76 late) and 232 (51%) of 453 ipilimumab-treated patients (160 early, 72 late). Median PFS on next-line systemic therapy for nivolumab-treated patients recurring early versus late was 4.7 versus 12.4 months (24-month rates, 16% v 31%); median OS was 19.8 versus 42.8 months (24-month rates: 37% v 73%). In response to subsequent therapy, patients on nivolumab with late versus early recurrence were more likely to benefit from anti-PD-1 monotherapy. Nivolumab-treated patients with either an early or late recurrence benefitted from an ipilimumab-based therapy or targeted therapy, each with similar OS. CONCLUSION: Postrecurrence survival was longer for patients who recurred >12 months. Patients on nivolumab who recurred early benefitted from SST but had better survival with ipilimumab-based regimens or targeted therapy compared with anti-PD-1 monotherapy.

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure2 个面板

FIG 1.

Kaplan-Meier curve of PFS from time of subsequent systemic therapy for patients who received nivolumab on study and had a recurrence at any time and by recurrence at ≤12 or >12 months from treatment initiation (A) and for patients who received ipilimumab on study and had a recurrence at any time and by recurrence at ≤12 or >12 months from treatment initiation (B). PFS, progression-free survival.

A

PFS

FIG 1. · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
B

PFS

FIG 1. · Panel B

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel B 是同一 FIG 1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

FIG 3.

Kaplan-Meier curve of OS from time of subsequent systemic therapy for patients who received nivolumab on study and had a recurrence at any time and by recurrence at ≤12 or >12 months from treatment initiation (A) and for patients who received ipilimumab on study and had a recurrence at any time and by recurrence at ≤12 or >12 months from treatment initiation (B). NR, not reached; OS, overall survival.

A

OS

FIG 3. · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

FIG 3. · Panel B

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel B 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 2.Twelve-month (A) and 24-month (B) PFS rates from time of subsequent therapy for patients who received nivolumab on study and had a recurrence ≤12 or >12 months from treatment initiation and 12-month (C) and 24-month (D) PFS rates from time of subsequent therapy for patients who received ipilimumab on study and had a recurrence ≤12 or >12 months from treatment initiation. PFS, progression-free survival.
非 KM Figure
FIG 4.Twelve-month (A) and 24-month (B) OS rates from time of subsequent therapy for patients who received nivolumab on study and had a recurrence ≤12 or >12 months from treatment initiation and 12-month (C) and 24-month (D) OS rates from time of subsequent therapy for patients who received ipilimumab on study and had a recurrence ≤12 or >12 months from treatment initiation. OS, overall survival.
非 KM Figure
FIG 5.(A) Nature of first unresectable recurrence in patients who received nivolumab, (B) nature of recurrence in patients who received ipilimumab, (C) sites of metastasis at first distant recurrence in patients who received nivolumab, and (D) sites of metastasis at first distant recurrence in patients who received ipilimumab, by time after random assignment (≤12 months or >12 months). a Patients could have been counted in more than one site recorded. b Other, including intramuscular, limb, neck, and trunk.
非 KM Figure